Human immunodeficiency virus protease inhibitors (PIs) modestly affect the plasma pharmacokinetics of tenofovir (TFV; ؊15% to ؉37% change in exposure) following coadministration with the oral prodrug TFV disoproxil fumarate (TDF) by a previously undefined mechanism. TDF permeation was found to be reduced by the combined action of ester cleavage and efflux transport in vitro. Saturable TDF efflux observed in Caco-2 cells suggests that at pharmacologically relevant intestinal concentrations, transport has only a limited effect on TDF absorption, thus minimizing the magnitude of potential intestinal drug interactions. Most tested PIs increased apical-to-basolateral TDF permeation and decreased secretory transport in MDCKII cells overexpressing P-glycoprotein (Pgp; MDCKII-MDR1 cells) and Caco-2 cells. PIs were found to cause a multifactorial effect on the barriers to TDF absorption. All PIs showed similar levels of inhibition of esterase-dependent degradation of TDF in an intestinal subcellular fraction, except for amprenavir, which was found to be a weaker inhibitor. All PIs caused a dose-dependent increase in the accumulation of a model Pgp substrate in MDCKII-MDR1 cells. Pgp inhibition constants ranged from 10.3 M (lopinavir) to >100 M (amprenavir, indinavir, and darunavir). Analogous to hepatic cytochrome P450-mediated drug interactions, we propose that the relative differences in perturbations in TFV plasma levels when TDF is coadministered with PIs are based in part on the net effect of inhibition and induction of intestinal Pgp by PIs. Combined with prior studies, these findings indicate that intestinal absorption is the mechanism for changes in TFV plasma levels when TDF is coadministered with PIs.
Tenofovir disoproxil fumarate (TDF; Viread, Gilead Sciences, Inc.), a prodrug of the nucleotide reverse transcriptase inhibitor tenofovir (TFV), is used to effectively deliver TFV across the gut wall. Following absorption, TDF rapidly degrades to TFV and TDF is not observed in the systemic circulation. When administered by itself, TFV has poor oral bioavailability (7) . TDF is a common once-a-day backbone for use with human immunodeficiency virus (HIV) protease inhibitors (PIs). Clinical trials have shown TDF with emtricitabine in combination with either lopinavir (LPV) or atazanavir (ATV), each boosted with ritonavir (RTV, or "r" when referred to as a boosting agent), to be efficacious and well tolerated (22, 30) .
Polypharmacy in HIV patients creates the potential for drug interactions (8, 35) . No interaction between PIs and TDF would be anticipated due to the lack of cytochrome P450 involvement in the elimination pathway of TDF or TFV (25) . However, modest changes in TFV plasma pharmacokinetic parameters have been reported for TDF coadministered with PIs. As summarized in Table 1 , PIs can be categorized into three different groups based on their effects on TFV plasma pharmacokinetics. The first group encompasses PIs that cause modest increases in TFV plasma exposure (area under the concentration-time curve from 0 h to time t [AUC 0-t ]) when coadministered with TDF and includes saquinavir (SQV)/r, darunavir (DRV)/r, LPV/r, the experimental PI brecanavir (BRV)/r, and ATV/r. The second group of PIs do not change the TFV AUC 0-t , although slight increases in the TFV maximal or minimal plasma concentration (C max and C min , respectively) have been reported, and include indinavir (IDV) and nelfinavir (NFV). The third group includes PIs that cause slight decreases in TFV levels. Tipranavir (TPV)/r causes a dose-dependent decrease in the TFV C max . Fosamprenavir (FPV; the phosphate prodrug of amprenavir [APV] ) dosed alone causes a decrease in the TFV AUC 0-t , C max , and C min , while FPV dosed as FPV/r causes a lesser decrease in TFV plasma C max , with no change in the AUC 0-t or C min .
The goal of the research described here was to determine if PIs can alter the intestinal absorption of TDF, causing the slight perturbations in the level of TFV observed in the systemic circulation. These studies were undertaken in light of the following observations suggesting that PIs may affect TDF absorption: (i) TDF absorption can be increased by a high-fat meal (3, 25) ; (ii) TDF intestinal absorptive flux was previously reported to be limited in vitro by esterase activity and efflux transport, based on increased Caco-2 cell permeability observed in the presence of fruit extracts and the transport inhibitor cyclosporine A (CsA) (43); (iii) esterase activity has also been noted to affect the absorption of TFV prodrugs in vivo, based on the correlation between increased esterase stability and higher oral bioavailability in the dog for different ester prodrugs of TFV (42) ; and (iv) PIs are known to inhibit the intestinal efflux transporter P-glycoprotein (Pgp) (27) . Detailed in vitro studies were designed to identify if Pgp is in-volved in TDF efflux and to determine the magnitude of the effect it has in limiting the absorption of TDF in the gastrointestinal tract. The effects of PIs on the permeation of TDF in vitro and the respective abilities of PIs to alter factors affecting TDF intestinal absorption, including esterase cleavage and efflux transport, were then determined. Results from these studies in combination with literature reports of similar drug interactions and the induction potential of PIs were used to develop a model explaining the relative effects of PIs on TFV circulating levels.
(This work was presented in part as poster 49 at the 7th International Workshop on Clinical Pharmacology of HIV Therapy, Lisbon, Portugal, 20 to 22 April 2006 [38] .)
MATERIALS AND METHODS
Reagents. TDF, its monoester intermediate metabolite (monoPoc TFV), and TFV were obtained from Gilead Sciences, Inc. (Foster City, CA). SQV was purchased from Moravek Biochemicals, Inc. (Brea, CA). NFV (mesylate salt), IDV (sulfate salt), RTV, APV, and LPV were purchased from Toronto Research Chemicals, Inc. (North York, Ontario, Canada). ATV (sulfate salt) was isolated from capsules. BRV and DRV were chemically synthesized. The transport inhibitor CsA, the Pgp substrate calcein-AM, and the esterase inhibitor di-isopropyl fluorophosphate were purchased from Sigma-Aldrich (St. Louis, MO). Cell culture supplies were obtained from Invitrogen (Carlsbad, CA), and HyClone fetal bovine serum was purchased from Fisher Scientific (Pittsburgh, PA). All other reagents were the highest quality available from Sigma-Aldrich.
Caco-2 and MDCKII cell transepithelial transport assays. Parental MadinDarby canine kidney (MDCKII) cells and MDCKII cells stably transfected with the human MDR1 gene (encoding Pgp; MDCKII-MDR1 cells) were kindly provided by Piet Borst of The Netherlands Cancer Institute. MDCKII-MDR1 cells have been characterized in a prior report (10) and were maintained as previously described (37) . MDCKII cells were seeded in 24-well plates at an initial density of 2.1 ϫ 10 4 cells/well and grown to confluence over 5 days prior to assay initiation. The permeability assay buffer for the donor and receiver chambers was Hanks balanced salt solution containing 10 mM HEPES and 15 mM glucose. The donor and receiver buffers were at pH 6.5 and 7.4, respectively, and the receiver well contained 1% bovine serum albumin. In some studies, the assay buffers also contained PIs (20 M) or the transport inhibitor CsA (10 M). All chambers were preincubated for 60 min with transport buffer containing the appropriate inhibitor to saturate any transporter binding sites. Following preincubation, fresh assay buffer containing inhibitor and TDF was added, and the assay was started. At each time point, 1 and 2 h, an aliquot was taken from the receiver chamber and replaced with fresh assay buffer. Samples were taken from the donor chamber at 0 and 2 h. Cells were dosed on the apical (A) or basolateral (B) side to determine A-to-B and B-to-A permeability, respectively, and were incubated at 37°C with 5% CO 2 in a humidified incubator. Each determination was performed in duplicate, and the permeation of control compounds (atenolol, propranolol, and vinblastine) was determined to meet acceptance criteria for each assay plate.
Bidirectional permeability studies were done using confluent monolayers of the human colon carcinoma cell line Caco-2 (16) seeded in 12-well plates essentially as previously reported (37) . The effects of PIs on the permeation of TDF were studied following a 30-min preincubation of cell monolayers with 20 M PIs in transport buffer to allow for saturation of transporter binding sites. Following preincubation, fresh assay buffer containing inhibitor and TDF was added, and the assay was started. Each determination was performed in duplicate, and the permeation of control compounds (atenolol, propranolol, and digoxin) was determined to meet acceptance criteria for each batch of assay plates. Levels of TDF and its metabolites in Caco-2 and MDCKII cell permeability studies were analyzed by liquid chromatography coupled to triple-quadrupole mass spectrometry (LC/MS/MS) as described below.
Pgp inhibition assay. The inhibition of Pgp-mediated transport was studied using the Pgp substrate calcein-AM and MDCKII-MDR1 cells. Studies were done with a 96-well fluorescence assay essentially as described previously (37) . Twofold serial dilutions of PIs, with a starting concentration of 50 M (seven individual concentrations were tested), were added simultaneously with calcein-AM to parental and MDCKII-MDR1 cells. All studies were done in duplicate.
Inhibition of TDF degradation in a human intestinal subcellular fraction. Human intestinal S9 (a subcellular fraction) was purchased from XenoTech LLC (Lenexa, KS). Reactions were done with a 1-mg/ml protein concentration. TDF was incubated at 2 M in the presence or absence of PIs or the known esterase inhibitor di-isopropyl fluorophosphate. All PI inhibition studies were done at 50 M, except for those with RTV, where the dose dependence of inhibition was assessed at concentrations of 10, 50, and 100 M. The potent esterase inhibitor di-isopropyl fluorophosphate was incubated at 2 M. Reactions were done in duplicate at 37°C. After 30 and 60 min, TDF degradation was stopped by the addition of 67% acetonitrile in water. The protein precipitate was removed by centrifugation, and the supernatant was analyzed by LC/MS/MS as described below.
Quantitation of TDF and its metabolites by LC/MS/MS. Levels of TDF and its metabolites were quantified using LC/MS/MS methods by comparing the relative peak areas of samples to standard curves for known concentrations prepared with appropriate sample matrices. Levels of TDF and monoPoc TFV were determined in MDCKII cell permeability assays and intestinal S9 stability assays by reversed-phase chromatography on a BEH C 18 column (1.7 m by 50 mm by 2.1 mm), with a gradient from 1% to 80% acetonitrile over 3.5 min and a flow rate of 0.9 ml/min, on an Acquity ultra-performance LC system coupled to a Micromass Quatro Premier XE MS/MS system running in positive ionization and multiple reaction monitoring modes (the column, LC system, and mass spectrometer were all purchased from Waters, Milford, MA). Due to insufficient sensitivity for TFV with the Micromass instrument, the levels of TFV, monoPoc TFV, and TDF were determined in select intestinal S9 stability and MDCKII cell permeability studies by using an API 4000 MS/MS system (Applied Biosystems/ MDS Sciex, Foster City, CA) running in positive ionization mode and monitoring the parent/daughter mass transitions of 520/270, 404/270, and 288/176, respectively. An LC flow rate of 1 ml/min, with 0.2% formic acid as the buffer and a linear gradient from 0 to 62% acetonitrile over 3 min, was used. A Synergy Hydro RP 80 column (4 m by 50 mm by 4.6 mm; Phenomenex, Torrance, CA) was used to separate the analytes. Similarly, levels of TDF were quantitated following the addition of acetonitrile containing 0.4% formic acid in Caco-2 cell assays by a reversed-phase high-performance LC method coupled to positive-mode MS/MS at Absorption Systems (Exton, PA).
Data analysis. The A-to-B and B-to-A apparent permeability coefficients (P app ) for Caco-2 and MDCKII cells were calculated using the equation
, where dC/dt is the change in concentration over time, as measured at 60 and 120 min, in M/s; V r is the volume of the receiver well, in cm 3 ; A is the area of the cell monolayer, in cm 2 ; and C 0 is the initial concentration in the donor well, in M. The percent recovery was calculated by comparing the total amount of material in the donor and receiver chambers at the end of the experiment relative to the amount added to the donor chamber at the beginning of the experiment. The efflux ratio (ER) was defined as the B-to-A P app divided by the A-to-B P app . The binding constant for efflux saturation was calculated by comparing the ER measured at the lowest concentration of TDF tested (1 M) to that observed at higher concentrations, using the following equation: The amount of PI required to inhibit Pgp-dependent calcein-AM transport was determined by fitting the percent increase in intracellular fluorescence in the presence of different PI concentrations to a hyperbolic curve. The rates of TDF degradation in intestinal S9 studies were determined by fitting the data to a single-exponential-decay curve. The percent inhibition of TDF degradation was then obtained by comparing the observed rate of TDF degradation with the addition of dimethyl sulfoxide (control) to that obtained in the presence of inhibitor. Where appropriate, the statistical significance of differences observed was assessed using two-tailed Student's t tests.
RESULTS
Dose-dependent effect of efflux transport on TDF permeation. TDF (formula weight, 635) is given as a single 300-mg tablet once a day, and assuming rapid dissolution into approximately 250 ml of intestinal content, the pharmacologically relevant intestinal concentration should be around 2 mM. The dose-dependent bidirectional permeation of TDF was determined at concentrations approaching levels anticipated in the gastrointestinal tract, using the Caco-2 cell intestinal permeability model. The A-to-B P app of TDF increased linearly Ͼ10-fold between concentrations of 1 and 1,000 M (Fig. 1A) . Over this TDF concentration range, the ER for TDF was found to be saturable, yielding an apparent binding constant for efflux saturation of 144 M (concentration required to cause 50% saturation) (Fig. 1B) , reflecting a decrease in the ER, from 25 at 1 M TDF to 2.6 at 1,000 M TDF.
Pgp-mediated transport of TDF in MDR1-transfected MDCKII cells. Earlier studies have indirectly inferred that TDF absorption is affected by Pgp-mediated efflux based on the effect of the efflux transport inhibitor CsA (38, 43) . To verify that Pgp contributes to TDF efflux, permeability studies were done with parental and MDR1-transfected MDCKII cells. TDF had a 3.2-fold lower forward permeation level and a 16-fold higher ER in MDCKII-MDR1 cells than in parental cells (data not shown). Quantitation of the TDF metabolites monoPoc TFV and TFV during TDF permeability studies with MDCKII-MDR1 cells showed minimal conversion (combined recovery in the donor and receiver wells was Ͻ5% of the original TDF concentration) and no marked contribution to total permeation (data not shown).
Effects of PIs on bidirectional permeation of TDF through monolayers of MDCKII-MDR1 and Caco-2 cells. Lower than pharmacologically relevant concentrations of TDF were used in cell-based permeability studies in order to increase efflux, facilitating the accurate assessment of the relative effects of PIs on TDF permeation. Having established the Pgp-dependent efflux of TDF, the effects of PIs on the efflux of TDF in MDCKII-MDR1 cells were assessed. PIs decreased the efflux of TDF in Pgp-overexpressing cells (Fig. 2) . The PIs BRV, NFV, LPV, and RTV were the most potent inhibitors of TDF efflux, while DRV, IDV, and APV showed smaller effects. We could not assess the effects of TPV due to insufficient material, Student's unpaired two-tailed t tests, assuming equal variance ( * , P Ͻ 0.05; ** , P Ͻ 0.01; *** , P Ͻ 0.001).
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on October 14, 2017 by guest http://aac.asm.org/ but it has been reported to be a weak Pgp inhibitor (Aptivus package insert; Boehringer Ingelheim). In order to study the effects of select PIs on the permeation of TDF in a more physiologically relevant model of gastrointestinal absorption, bidirectional permeability studies were done with Caco-2 cells (16) . The effects of LPV, ATV, RTV, SQV, IDV, and APV on the permeation of TDF were compared to those of the potent efflux inhibitor CsA and the esterase inhibitor di-isopropyl fluorophosphate (Fig. 3) . CsA and di-isopropyl fluorophosphate increased the forward permeation of TDF by 1.4-and 2.5-fold, respectively. The results for CsA and di-isopropyl fluorophosphate observed here were not unlike those found previously by others for CsA and fruit extracts (43) . RTV, LPV, ATV, and SQV caused greater increases in the TDF A-to-B P app than did CsA. Comparison of permeation in both the A-to-B and B-to-A directions showed that CsA caused a near complete blockage of TDF efflux transport, while di-isopropyl fluorophosphate similarly increased the P app of TDF in the A-to-B and B-to-A directions. Consistent with the results from MDCKII-MDR1 cells, APV and IDV were among the weakest and LPV and RTV were among the strongest inhibitors of TDF efflux in Caco-2 cells.
Inhibition of intestinal ester hydrolysis of TDF by PIs. The potential for inhibition of TDF hydrolysis by PIs was assessed in a human intestinal subcellular fraction (S9). The major product of TDF degradation in S9 was the intermediate monoester metabolite of TFV (monoPoc TFV), with lower levels of TFV (data not shown). RTV caused a dose-dependent decrease in TDF degradation (Fig. 4A) . Di-isopropyl fluorophosphate and PIs were found to inhibit TDF degradation (Fig. 4B) and, concomitantly, to decrease the appearance of its metabolites. PIs were tested at a concentration near their solubility limits to model pharmacologically relevant concentrations potentially formed following dosing in the gastrointestinal tract Values represent the means Ϯ standard deviations for three to six independent experiments done in duplicate. The statistical significance of changes in the rate of TDF degradation in the presence of inhibitors relative to that with no inhibitor was assessed by Student's unpaired two-tailed t tests, assuming equal variance ( * , P Ͻ 0.05; ** , P Ͻ 0.01; *** , P Ͻ 0.001).
VOL. 51, 2007
PIs AFFECT TDF ABSORPTION 3501 on October 14, 2017 by guest http://aac.asm.org/ bition in 50 M incubations of approximately 100% and 15%, respectively. The calculated 50% inhibitory concentrations (IC 50 s) for the PIs and CsA are summarized in Table  2 . The rank order of PIs was similar to that observed based on their effects on the bidirectional permeation of TDF through MDCKII-MDR1 cells. When tested at concentrations ranging between 0.78 and 50 M, the most potent PIs, LPV, NFV, and BRV, inhibited the efflux of calcein-AM by 50% at approximately 20 M. APV, IDV, and DRV were the weakest inhibitors (IC 50 Ͼ 100 M).
DISCUSSION
The observation of efflux in Caco-2 cells illustrates that TDF is a substrate for one or more intestinal efflux transport pumps. The differential transport of TDF observed in parental and Pgp-overexpressing MDCKII cells suggests that this highly expressed intestinal efflux pump is at least partly responsible for this phenomenon. There is a synergistic interaction between intestinal Pgp transport and cytochrome P450 3A4 degradation in limiting the oral bioavailability of substrates for both proteins (34, 46) . The interaction is facilitated by Pgp increasing the intracellular residence time of compounds in intestinal cells and allowing for further degradation by cytochrome P450 3A4. Our results support the hypothesis that a similar interplay between intestinal Pgp and esterase activity may play a role in limiting the intestinal absorption of TDF. However, the measurement of an apparent binding constant for efflux transport of 144 M, combined with the high solubility of TDF, suggests that efflux is largely saturated during TDF absorption (Fig.  1B) . Of primary importance in the current discussion of drug interactions, this suggests the potential for only minimal changes in TDF absorption and resulting TFV circulating levels upon coadministration with agents affecting either esterase cleavage or Pgp transport.
PIs were established to be inhibitors of the molecular barriers to TDF absorption, based on results in bidirectional permeability, intestinal extract stability, and fluorescent Pgp inhibition assays. Their multifactorial effect on efflux transportand esterase-dependent permeation of TDF through Caco-2 cell monolayers was likely the reason that SQV, ATV, LPV, and RTV caused similar or greater effects on the TDF A-to-B P app than did the near complete blockage of efflux by CsA. Evidence for the role of Pgp in the efflux component of this interaction can be drawn from the effects of PIs on Pgp-dependent efflux in MDCKII-MDR1 cells. However, these results do not eliminate the potential for a contribution by other intestinal efflux pumps known to be expressed in Caco-2 cells (16) . RTV, ATV, and LPV were observed in both MDCKII-MDR1 and Caco-2 cells to increase the A-to-B P app of TDF and to decrease TDF efflux, likely explaining the presence of these PIs in combinations causing increases in TFV exposure in vivo. Alternatively, the lower inhibition caused by APV and IDV in transepithelial permeability, esterase activity, and Pgp transport assays may explain why FPV and IDV do not cause increased TFV levels in patients.
There is, however, a partial disconnect between the increase in TDF permeation observed for most PIs in vitro and the spectrum of effects that PIs and their combinations have on plasma TFV levels clinically. This inconsistency is most apparent in the decreases in TFV levels observed when TDF is coadministered with TPV/r, FPV/r, and most significantly, FPV. A clue to the mechanism for the decreased TFV levels observed with these PIs is evident in the drug interaction between the strong intestinal Pgp inducer rifampin (14, 15) and TDF. When TDF was coadministered with rifampin, a slight decrease in TFV plasma levels (16% C max and 12% AUC 0-t ) was observed (9) . The similarity in the effects of rifampin and these PIs suggests a common mechanism for the decreased TFV levels. Consistent with this hypothesis, TPV is known as a strong inducer of metabolizing enzymes (Aptivus product insert; Boehringer Ingelheim). While they are less marked inducers than TPV or rifampin, both NFV and APV induce intestinal Pgp after repeat dosing in the rat (18) . Studies with a colonic cell line have shown the rank order of Pgp induction of tested PIs to be RTV Ͼ NFV Ն APV Ͼ SQV Ͼ IDV (33), and NFV also induces Pgp expression in CD4 ϩ and CD8 ϩ lymphocytes in vitro (11) . Indeed, the intestinal Pgp induction potential of NFV, APV, rifampin, and TPV may not be coincidental with their minimal (NFV) or slightly detrimental (FPV, rifampin, and TPV) effects on TFV circulating levels. The ability of PIs to both inhibit and induce Pgp illustrates that their net effect on intestinal Pgp activity will be a balance between their inhibition and induction potentials. Digoxin levels have been shown to be sensitive to intestinal Pgp activity (14, 17) , and the strong Pgp inducers and weak Pgp inhibitors TPV/r and rifampin have been shown to reduce digoxin's AUC 0-t (14, 45) . Alternatively, the digoxin AUC 0-t is increased by the potent Pgp inhibitors RTV and LPV/r (21, 31). Similarly, net inhibition of intestinal Pgp has been observed for LPV/r, based on its effects on the oral bioavailability of the Pgp substrate fexofenadine in healthy volunteers (44) . While it was observed to be an inducer of Pgp, the net effect of ATV on Pgp activity in vitro has been shown to be inhibition (32) . A model for the effects of PIs on TDF absorption, including intestinal esterase inhibition and the net effect of intestinal Pgp inhibition and induction, is presented in Fig. 5 .
It has been proposed that the clinically observed changes in TFV circulating levels are due to PI inhibition of the multidrug resistance-related protein 2 (MRP2)-dependent apical renal b HIV PIs were tested at concentrations of up to 50 M in the absence of serum proteins. All PIs showed significant dose-dependent inhibition of Pgp during the assay, although many did not attain Ն25% inhibition at 50 M, and their IC 50 values are reported as Ͼ100 M.
transport of TFV in the kidney during the process of active tubular secretion. Furthermore, blockage of MRP2-mediated renal elimination of TFV has been proposed to cause the accumulation of TFV in renal proximal tubule cells, resulting in an alteration in the renal safety profile of TDF (20, 28, 39, 47) . However, two independent reports have shown that the renal transport of TFV is likely mediated by MRP4, not MRP2 (19, 36, 37) . Further studies have shown that PIs have minimal potential to inhibit the active renal tubular secretion of TFV mediated by influx from the blood via the human organic anion transporters 1 and 3 and by efflux from proximal tubule cells into the urine by MRP4 (6) . Renal accumulation of TFV due to PIs is also not consistent with other observations, including (i) the low incidence of TDF-related renal adverse events in the context of combination therapy, with or without PIs (the TDF renal safety profile was recently reviewed by Sax et al. [41] and by Gitman et al. [13] ); and (ii) the lack of overlapping recognition of TFV and PIs by renal efflux transporters (6), unlike the common interaction of PIs and TDF with the intestinal efflux transporter Pgp illustrated here.
We have shown that all PIs have the potential to modulate the intestinal absorption of TDF. The differential changes in circulating TFV levels observed clinically with different PIs are likely related to the relative abilities of PIs to (i) inhibit TDF hydrolysis in intestinal tissue, (ii) inhibit Pgp-mediated efflux of TDF, and (iii) induce Pgp expression. Our work also suggests that the magnitude of perturbations in TDF absorption caused by concomitant agents should be limited by partial saturation of intestinal transport. 
